Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Share subscriptions based on stock option 2013B and stock option 2013C

CapMan Plc Stock Exchange Release                     8 May 2019 at 08:30 a.m. UTC+3 Share subscriptions based on stock option 2013B and stock option 2013C Between 22 January 2019 and 15 April 2019, a total of 240,775 CapMan Plc new shares have been subscribed for with the company's stock options 2013B and a total of 20,748 company’s new shares have been subscribed for with the company’s stock options 2013C. The entire subscription price of EUR 210,594.29 shall be recorded into the invested non-restricted equity fund. As a result of the subscriptions, the number of CapMan shares

Raisio plc: Interim Report 1 January - 31 March 2019

Raisio plc, Interim Report 8 May 2019 at 8:30 a.m. Finnish time RAISIO'S INTERIM REPORT 1 JANUARY - 31 MARCH 2019: RAISIO STARTED THE IMPLEMENTATION OF ITS NEW STRATEGY, NET SALES DECLINE STOPPED Financial development in brief, continuing operations · The Group’s net sales totalled EUR 49.9 (49.7) million. Comparable EBIT was EUR 5.0 (6.3) million, accounting for 10.0 (12.6) % of net sales. EBIT was EUR 5.0 (4.4) million, accounting for 10.0 (8.8) % of net sales. · As from January 2019, Raisio’s reportable segments are Healthy Food and Healthy Ingredients. · The Healthy

Apetit to update operational indicators

Apetit Plc, Stock Exchange Release, 8 May 2019 at 8:25 a.m.Apetit Plc is updating its operational indicators and in the future the company will present operational indicators without the IAS-2 Inventories -standard capitalisation of fixed costs at inventory value. Due to harvest-time production, the IAS-2 accounting practice means that most of the profit is accrued in the last two quarters of the year, which weakens the result for the first two quarters and causes seasonal variation. As a result of this change, the information made available to investors will also better match the

Double-digit growth for all strategic brands and DKK 4,234 million in revenue and DKK 1,200 million in EBIT

HIGHLIGHTS · Revenue reached DKK 4,234 million in the first quarter of 2019 representing a decline of 8% (6% in local currencies) compared to the same period last year. The decline was expected and a result of generic competition on Onfi[®] · Revenue of Abilify Maintena[®] increased 27% to DKK 462 million (24% in local currencies) · Revenue of Brintellix[®]/Trintellix[®] increased 29% to DKK 601 million (27% in local currencies) · Revenue of Northera[®] increased 10% to DKK 435 million (3% in local currency) · Revenue of Rexulti[®]/Rxulti[®] increased 30% to DKK 481

HKScan Group’s Interim Report 1 January–31 March 2019: The company's loss decreased clearly – balancing finances started

HKScan Corporation             INTERIM REPORT               8 May 2019               at 8:15 EESTHKScan Group’s Interim Report 1 January–31 March 2019: The company's loss decreased clearly – balancing finances started JANUARY–MARCH 2019 IN BRIEF ·  Net sales were EUR 401.8 (411.0) million. ·  EBIT was EUR -14.7 (-18.3) million, and the EBIT margin -3.6 (-4.4) per cent. Danish asset prices were depreciated by 4,5 million after impairment testing. ·  Comparable EBIT was EUR -10.1 (-18.1) million. The corresponding EBIT margin was -2.5 (-4.4) per cent. ·  EPS was EUR -0.33 (-0.

Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma

·  The trial is now fully recruited, with a total of 31 patients enrolled   ·  Data read-outs expected around New Year Oslo, Norway, 8 May 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that it has completed patient enrollment in the phase Ib/II trial of ONCOS-102 in combination with chemotherapy in unresectable malignant pleural mesothelioma (MPM).  The trial consists of a phase Ib safety lead-in part followed by a randomized, open label phase II part, assessing the

HKScan’s Board of Directors decided on new plan periods within the share-based long-term incentive scheme for key employees

HKScan Corporation             Stock Exchange Release 8.5.2019, at 8.05 (EEST)HKScan’s Board of Directors decided on new plan periods within the share-based long-term incentive scheme for key employees The Board of Directors of HKScan Corporation has approved new plan periods within the share-based long-term incentive scheme for HKScan's key employees. The long-term incentive scheme comprises a Performance Share Plan (also “PSP”) and a Restricted Share Plan (also “RSP”). HKScan announced the establishment of the share-based long-term incentive scheme with a stock exchange release on 7

BerGenBio ASA: Results for the First Quarter 2019

· Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia · Advanced lung cancer (NSCLC): Additional cohort added in trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® · Anti-AXL antibody, BGB149, commenced phase I safety and pharmacokinetic clinical trial.Bergen, Norway, 08 May 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer

Fortum enters into partnership with Spinnova to continue building its bio-based ecosystem

Fortum and Spinnova Oy, a developer of sustainable textile fibre, have entered into a partnership to produce fibre from agro residues and woody biomass. The cooperation is another step towards Fortum’s strategy to build options for significant new businesses that improve resource efficiency and provide smart solutions for a cleaner world. Fortum is currently evaluating different biomass fractionation technologies and has identified microfibrillated cellulose (MFC) as one potential intermediate product from the cellulose fraction. Spinnova’s technology, presently in the large industrial-

Nightingale Health collaborates with National University of Singapore to realise the prevention of chronic diseases in South East Asia

Nightingale Health Ltd., the Finnish innovator of an internationally recognised blood analysis technology for studying chronic diseases today announced the first step in a major collaboration with the National University of Singapore (NUS), one of the world’s leading universities to realise the prevention of chronic diseases in South East Asia.In the first phase of the collaboration, Nightingale will provide NUS with novel biomarker data for 5,000 blood samples from the Singapore Multiethnic Cohort (MEC) collection, representing the Malay, Indian and Chinese populations in Singapore. The

RepRisk integrates Sustainability Accounting Standards Board (SASB) Framework

Investors can identify environmental, social, and governance (ESG) risks that are most material to the industries they invest inRepRisk, a global leader in data science, specializing in premium ESG and business conduct risk research, is pleased to announce the application of the SASB Materiality Map® in its risk management and compliance solutions. RepRisk is mapping its core research scope of 28 ESG issues against the 26 sustainability issues that comprise the SASB Materiality Map®. The Map identifies those sustainability issues that are likely to affect the financial condition or

Invitation to presentation of Multiconsult ASA's first quarter 2019 results

Multiconsult ASA's first quarter 2019 results will be released on Thursday 23 May at 07:00 CET. The complete report and presentation will be available at www.multiconsult-ir.com and www.newsweb.no.A presentation of the first quarter 2019 results will be held in Norwegian at 09:00 CET, followed by a conference call at 10:30 CET in English. The Norwegian presentation will be held at Hotel Continental, Stortingsgaten 24/26, Oslo.The presentation will be held by CEO Grethe Bergly and CFO Hans-Jørgen Wibstad. A live webcast from the Norwegian presentation can be accessed at www.

Magnolia Bostad and Heimstaden Bostad form JV for the development of residencies in Upplands-Bro

Magnolia Bostad and Heimstaden Bostad have formed a joint venture with the aim of jointly developing around 800 residencies in the new southern part of Bro, in Upplands-Bro municipality. The land was owned by Magnolia Bostad and is being acquired by the joint venture company.The joint venture has entered into an agreement to acquire part of Magnolia Bostad's Brogårdstaden project in the southern part of Bro, in Upplands-Bro municipality. The land has legally binding zoning planning and the buildings will consist of residential apartments in multi-dwelling buildings and small houses

Ambea’s interim report January-March 2019

CEO comment:In the first quarter, high rates of occupancy and effective cost control in existing Ambea operations continued, while the integration of Aleris Omsorg started well. Our initial view of the potential in the acquisition of Aleris Omsorg was confirmed during the quarter, and the integration is going better than planned in both Sweden and Denmark. In Norway, a major operational restructuring project has commenced to introduce Ambea’s processes into administration, governance and business operations, and to transition from temporary consultants to permanent employees. Net sales

Interim Report Q1, 2019

Phase 3 study continues according to plan“This first quarter of 2019, we were busy ensuring that the recruitment efforts for our pivotal phase 3 study NefIgArd remain on track, focusing on site initiation visits and supporting our CRO in their work to ensure that all sites are brought online on a timely manner. During the quarter we also receive orphan designation (ODD) by the US Food and Drug Administration (FDA) for our pipeline indications, Autoimmune hepatitis (AIH) and Primary biliary cholangitis (PBC), two orphan indications focused on chronic liver disease.” Renée Aguiar-Lucander,

Nel ASA: First Quarter 2019 Results

(Oslo, May 8, 2019) Nel ASA (“Nel”) reported revenues in the first quarter of 2019 of NOK 122.4 million, up from NOK 112.5 million in the first quarter of 2018, representing a growth of 9%. Nel has received several important purchase orders ("PO's") during 2019, has an all-time high pipeline and reiterates the strong market outlook. “Nel has a solid order intake so far in 2019, reflecting the attractive market opportunities provided by our leading technology across segments. The order for a 4.5 MW alkaline electrolyzer solution from Hybrit is an important example on how we’re working to

EVRY ASA: Continuing organic growth, stable margins and strong improvement in cash performance

(Fornebu, 8 May 2019) The EVRY Group reported total revenue of NOK 3 330 million in the first quarter of 2019, an improvement from NOK 3 208 million in the first quarter of 2018. This represented an organic growth of 3.6% in the first quarter of 2019 up from 0.5% compared to the same quarter last year.The company delivered EBITA of NOK 332 million in the first quarter, up from NOK 320 million in the first quarter last year. The EBITA margin of 10.0% in the first quarter of 2019 was in line with the corresponding quarter of 2018. CEO Per Hove, comments: - I am pleased to announce that

The many lives of rock material

YIT CORPORATION News, May 8, 2019 08:00Finnish bedrock consists mainly of durable rock material. YIT’s operations involve many phases in the life cycle of rock, such as extraction, mineral aggregate refining, as well as the recycling and reuse of aggregates in asphalt, for example. The story of rock material starts deep in the core of Finnish bedrock, which can be up to 3,000 million years old. Finnish bedrock is durable and it mainly consists of solid bed. Rock has been used as material for as long as mankind has built constructions. Today, rock material is used in nearly all

SSG: First quarter 2019 results

(Oslo, 8 May 2019) Self Storage Group ASA (Self Storage Group, OSE:SSG) reported revenues of NOK 61.6 million in the first quarter of 2019, an increase from NOK 58.3 million in the corresponding quarter in 2018, and an adjusted EBITDA of NOK 34.4 million (15.6).  Adjusted EBITDA excluding impacts from the implementation of IFRS 16 was NOK 19.3 million. The company has a current lettable area of 117 500 m2, with a solid pipeline of potential new developments, providing a strong platform for further profitable growth and expansion.“The first months of the year is usually low season for self-

Interim report, Q1 2019

Highlights first quarter — Net revenue amounted to 418 MSEK (315 MSEK), an increase of 33% compared to the first quarter of 2018.  — EBITDA amounted to 154 MSEK (103), an increase of 50%.  — EBIT amounted to 113 MSEK (73), an increase of 54% compared to the same quarter last year.  — The net result amounted to 69 MSEK (46).  — The net result per share undiluted amounted to 2.93 SEK (2.05). The net result per share diluted amounted to 2.91 SEK (2.04).  — Net debt amounted to 485 MSEK (355) and the adjusted leverage ratio was 0.9x.  Comments from the CEO “The first

Sedana Medical AB (publ), Interim report Q1, 2019

Clear regulatory pathway to approval in EU and USAFirst quarter, January - March 2019 ·  Net sales during the first quarter amounted to KSEK 17,814 (15,487) corresponding to an increase of 15% compared with the same period in 2018. ·  Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to KSEK -2,641 (-788) KSEK. This corresponds to an EBITDA margin of -14,8% (-5,1%). ·  Earnings before interest and taxes (EBIT) amounted to KSEK -3,660 (-1,730), which corresponds to an EBIT margin of -20,5% (-11,2%) ·  Cash flow from operations before changes

Zalaris sets profitability target and action plan for 2019

The first quarter of 2019 is marked by continued revenue growth and the successful launch of new contracts with top-tier clients, but also profitability below target levels.“We aim to continue being a growth company. However, our short-term priority is to return to the margin level that we had prior to our acquisitions – and our target is to produce a consistent 10% adjusted EBIT by the last quarter of 2019”, says Hans-Petter Mellerud, Zalaris’ CEO and founder. The following actions have been initiated to reach the profitability target: · Centralizing support functions as Finance,

Outokumpu sells real estate in Germany for EUR 90 million

Outokumpu OyjInside informationMay 8, 2019 at 8.00 am EEST Outokumpu sells real estate in Germany for EUR 90 million Outokumpu and CG Gruppe AG have signed an agreement regarding the sale of Outokumpu’s real estate in Benrath, Germany. The value of the transaction is EUR 90 million. The deal is expected to be closed in the third quarter and the cash proceeds will be used to reduce debt. The positive impact on EBITDA from the transaction is expected to be approximately EUR 68 million which will be reported as an adjustment in the third-quarter results. The sold land has been

There are no items matching the current filter
There are no more items matching the current filter
Back to top